Skip to main content
Delfa

← Trials/Trial dossier/NCT00142324

UnknownPhase 4

CALM-AD

A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention

Asset

Donepezil

Listed sites

8

Recruiting sites

-

Enrollment

190

Study population

Alzheimer’s disease

Key I/E criterion

Alzheimer's disease

Primary endpoint

Cohen Mansfield Agitation Inventory

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDISRCTN62185868
NCT IDNCT00142324

Timeline

Milestones

Study start2003-11 (month precision)
Study first posted2005-09-02estimated
Study completion2005-12 (month precision)
Last update posted2005-12-14estimated

Assets

Drug assets

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age40 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

a diagnosis of dementia consistent with Diagnostic and Statistical Manual of Mental Health Disorders, revised 3rd edition (DSM-III-R) (APA, 1987) National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) diagnostic criteria for probably or possible AD (MKhann et al, 1984) (Appendix 6) clinically significant agitation (defined as causing distress to patient and at least moderate management problems for carers on at least two days per week for a two week period, together with a Cohen Mansfield Agitation Inventory (CMAI) (Cohen-Mansfield, 1986) (Appendix 11 A) score >39 age >39 years resident in care facility or community living with a carer not receiving treatment with neuroleptics or cholinesterase inhibitors currently or in the past four weeks and responsible clinician not considering treatment with cholinesterase inhibitor for the next 16 weeks taking into account the clinical evidence base and NICE guideline (NICE, 2001) patient with capacity willing to consent to study or will to participate in study if lacking capacity carer with capacity willing to consent to study and in agreement for patient lacking capacity to participate if patient willing to participate

Exclusion criteria

known sensitivity to Donepezil severe, unstable or uncontrolled medical conditions apparent from history, physical examination or investigations current evidence of delirium patient meets criteria for Probably Dementia with Lewy Bodies (McKeith et al, 1996) low probability of treatment compliance

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition
2
Behavior / neuropsychiatric
2
Other clinical outcomes
1

Global cognition

2 endpoints
Secondary/protocol endpoint

Standardized Mini-Mental State Examination

Mini-Mental State Examination (MMSE)

descriptive

Secondary/protocol endpoint

Severe Impairment Battery

descriptive

Behavior / neuropsychiatric

2 endpoints
Primary/protocol endpoint

Cohen Mansfield Agitation Inventory

descriptive

Secondary/protocol endpoint

Neuropsychiatric Inventory

Neuropsychiatric Inventory (NPI)

descriptive

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint

Clinical Global Impression of Severity/Change

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.